Episode 38: MCAS Explained: Mast Cell Activation, Mystery Symptoms, and Why It’s So Debated

<p>After four years of optimizing hormones, I kept running into patients whose fatigue and strange, multi-system symptoms didn’t fit perimenopause, or anything else, and whose labs looked normal. Many had been down the TikTok rabbit hole and arrived asking, “could this be MCAS?” So this episode is me breaking it down, not as an expert (I want to be very clear I’m not), but as a clinician trying to spread awareness, because I believe our patients deserve to be heard and thoroughly evaluated.</p><p>We start with the basics: the critical difference between mast cell activation (normal, and part of any allergic reaction) and mast cell activation syndrome, what the pattern can look like, and why the story and timing matter far more than any single symptom. Then we get into the genuine scientific debate, the stricter established criteria, the broader framework proposed by Dr. Lawrence Afrin and Dr. Tania Dempsey that I’ve immersed myself in, and the counter-arguments warning of over-diagnosis. We also cover the real limits of tryptase testing, and why ruling other things out matters as much as ruling MCAS in.</p><p>Finally, I share the slow-and-steady approach: identify your triggers, track your patterns, and work closely with a provider. Above all, one safety point that cannot be overstated: MCAS can involve anaphylaxis, which is a medical emergency, and no supplement or antihistamine is a substitute for emergency care. </p><p>This episode is about staying curious, asking better questions, and refusing to stop looking just because someone says it is, or isn’t, MCAS.</p><p><br></p><p><strong>NOTES ON THE EVIDENCE</strong></p><p>MCAS remains an evolving area of medicine. The most widely cited diagnostic frameworks generally emphasize three components:</p><p>However, experts continue to debate how strictly these criteria should be applied. Some clinicians and researchers argue that restrictive criteria may miss patients with chronic or less typical presentations. Others emphasize that broadening the diagnosis without objective evidence may increase misdiagnosis because many MCAS symptoms are nonspecific.</p><p>Laboratory testing also has limitations. Acute serum tryptase must be collected soon after symptom onset and compared with a baseline level obtained when the patient is well. Urinary mediators, including N-methylhistamine, leukotriene E4 and prostaglandin metabolites, may provide additional information, but they also require careful interpretation and are no